-
Mestranol and Reversible Lysosomal Stress in Microglia
2026-09-30
A 2026 zebrafish study identifies mestranol as an inducer of a reversible lysosomal storage–like state in microglia, marked by cargo accumulation, impaired intracellular digestion, and immune transcriptional suppression without increased neuronal apoptosis. The work provides a live in vivo model for investigating acquired microglial lysosomal stress and for separating lysosomal dysfunction from cell-death phenotypes.
-
DrPISA Expands Thermal Proteomics into Aggregates
2026-09-30
The DrPISA study introduces a deep eutectic solvent-assisted reverse PISA workflow that makes heat-aggregated proteins accessible to quantitative mass spectrometry. Its DES-48 solubilization chemistry and streamlined six-temperature design improve proteome coverage, reveal subtle stability changes, and identify previously under-recognized drug–protein interactions such as the celastrol-associated signal involving LULL1.
-
Phosphatase Inhibitor Cocktail 3: Workflow Guide
2026-09-29
Protect phosphorylation-dependent signals from cell and tissue lysis through Western blotting, co-immunoprecipitation, and phosphoprotein analysis. This workflow guide shows how a 100X DMSO formulation supports reproducible signaling studies while avoiding inhibitor carryover and sample-handling errors.
-
EdU Cell Proliferation Kit for RA S-Phase Studies
2026-09-29
The EdU Cell Proliferation Kit converts DNA synthesis into a sensitive, non-radioactive TMB signal for studying rheumatoid arthritis fibroblast-like synoviocytes, drug responses, and genotoxic stress. This practical guide connects ARL4C-driven synoviocyte biology with a controlled 5-ethynyl-2'-deoxyuridine proliferation assay, including workflow design and troubleshooting.
-
iRGD-RBCM Nanocarriers Improve Neuroblastoma PDT
2026-09-28
A 2026 Journal of Materials Science study developed iRGD-functionalized red blood cell membrane vesicles for TPOR delivery in neuroblastoma photodynamic therapy. The biomimetic carrier improved cellular uptake, apoptosis-associated activity, migration inhibition, and tumor growth control compared with free photosensitizer, while also highlighting important translational limitations.
-
HyperScribe™ T7 High Yield RNA Synthesis Kit Plus
2026-09-28
A practical guide to using HyperScribe™ T7 High Yield RNA Synthesis Kit Plus (SKU K1401) when preparing RNA for cell viability, proliferation, and cytotoxicity studies. It connects product specifications with cautious assay design and the preliminary evidence for FLCN mRNA rescue.
-
Phillygenin Targets Inflammation in Diabetic Nephropathy
2026-09-27
A 2025 study reports that phillygenin reduced inflammatory and apoptotic signals in high-glucose-exposed podocytes and improved kidney injury measures in db/db mice. By combining cell experiments, RNA sequencing, and in vivo pathway analyses, it links these effects to TLR4/MyD88/NF-κB suppression and PI3K/AKT/GSK3β-associated survival signaling, while leaving direct target engagement and clinical relevance to be established.
-
mCherry mRNA for Reliable Fluorescent Cell Assays
2026-09-26
Use a red fluorescent protein mRNA as a practical readout for delivery, expression, and cell-localization workflows—not as a direct metabolic sensor. This guide pairs the Cap 1 and modified-nucleotide design of EZ Cap™ mCherry mRNA with a controlled pilot workflow, assay choices, and troubleshooting steps.
-
Superoxide Dismutase (SOD) Activity Assay Kit Guide
2026-09-25
The Superoxide Dismutase (SOD) Activity Assay Kit (K2035) measures SOD activity through inhibition of WST-1 formazan formation, providing a colorimetric readout for oxidative stress studies. It is intended for research use with suitable biological samples, not for diagnostic or medical decisions; sample-matrix effects should be checked before comparing results.
-
Bay 11-7821 (BAY 11-7082): Practical Assay Guide
2026-09-25
Learn how to design and interpret cell-based experiments with Bay 11-7821 (BAY 11-7082), SKU A4210, while accounting for solvent, dose-response, and pathway-specificity considerations. Scenario-based guidance connects product data with published inflammatory research without overstating what the evidence establishes.
-
JNJ-10198409: PDGF Receptor Inhibitor Guide
2026-09-24
JNJ-10198409 is a platelet-derived growth factor receptor inhibitor that competitively targets the receptor’s ATP-binding site. Product information reports nanomolar activity in human coronary artery smooth muscle cells and positions the compound for preclinical proliferation, angiogenesis, and tumor-growth research.
-
Anti-HMGB1 Rabbit Monoclonal Antibody Guide
2026-09-24
The Anti-HMGB1 Rabbit Monoclonal Antibody (MA3057) supports detection of HMGB1 in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. Use it as a research reagent with assay-specific optimization; it is not intended for diagnostic, medical, or therapeutic use.
-
D-Luciferin Sodium Salt: Assay Mechanism & Use
2026-09-23
D-Luciferin sodium salt is a firefly luciferase substrate that produces light through an ATP-dependent reaction, supporting reporter assays and bioluminescence imaging. Its reported solubility and storage properties make it useful for cell viability and metabolism monitoring when assay controls distinguish reporter signal from biological interpretation.
-
Hepatic sEH, Nrf2, and Osteoporosis
2026-09-23
A recent Free Radical Biology and Medicine study identifies hepatic soluble epoxide hydrolase as a regulator of osteoclastogenesis through circulating 14,15-EET, 14,15-DHET, inflammatory cytokines, and Nrf2 signaling. Its clinical, animal, genetic, pharmacological, and transcriptomic evidence supports a liver–bone axis that may guide studies of redox imbalance and osteoporosis.
-
DNA–RNA Methylation Drives EGFR-TKI Resistance
2026-09-22
The reference study identifies a coordinated DNA 5-methylcytosine and RNA m5C mechanism that shifts MZF1 splicing toward the zinc-binding-deficient MZF1S isoform in EGFR-TKI-resistant NSCLC. Its findings connect UHRF1/DNMT1, NSUN7/YBX1, and SRSF1/SRSF3 activity to therapeutic resensitization, while suggesting methylation-regulated splice variants as biomarkers and intervention points.